Kura Oncology, Inc.
Symbool: KURA
NASDAQ
20.59
USDMarktprijs vandaag
-10.6467
Koers/Winst Verhouding
-0.2997
Koers/Winst Groei Verhouding
1.57B
MRK Kapitalisatie
- 0.00%
DIV Rendement
Kura Oncology, Inc. (KURA) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1880.65 | 424 | 438 | 518 | ||||||||||||||||
balance-sheet.row.short-term-investments | 1723.96 | 386.6 | 386.2 | 427.3 | ||||||||||||||||
balance-sheet.row.net-receivables | 2.8 | 2.8 | 0 | 0 | ||||||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-current-assets | 32.43 | 5.7 | 8.4 | 4.3 | ||||||||||||||||
balance-sheet.row.total-current-assets | 1907.21 | 432.5 | 446.4 | 522.3 | ||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 31.78 | 8.9 | 6.4 | 8.2 | ||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.long-term-investments | 0.61 | 0.2 | 0.2 | 0.2 | ||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-non-current-assets | 23.08 | 7.4 | 3.3 | 3.3 | ||||||||||||||||
balance-sheet.row.total-non-current-assets | 55.47 | 16.5 | 9.9 | 11.8 | ||||||||||||||||
balance-sheet.row.other-assets | 8.67 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-assets | 1971.35 | 448.9 | 456.3 | 534.1 | ||||||||||||||||
balance-sheet.row.account-payables | 6.4 | 2.3 | 1.5 | 3.2 | ||||||||||||||||
balance-sheet.row.short-term-debt | 6.9 | 1.5 | 2.3 | 2.3 | ||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.long-term-debt-total | 51.38 | 9.3 | 11.7 | 4.6 | ||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||
balance-sheet.row.other-current-liab | 109.76 | 31.5 | 20.2 | 17 | ||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 60.43 | 16.4 | 12 | 5 | ||||||||||||||||
balance-sheet.row.other-liabilities | -23.9 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.capital-lease-obligations | 25.89 | 6.4 | 4.9 | 6.9 | ||||||||||||||||
balance-sheet.row.total-liab | 155.48 | 51.7 | 36 | 27.4 | ||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.common-stock | 0.03 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.retained-earnings | -2811.11 | -721.4 | -568.8 | -433 | ||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -10.84 | -1.3 | -8 | -1.8 | ||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 3514.16 | 1120 | 8 | 1.8 | ||||||||||||||||
balance-sheet.row.total-stockholders-equity | 692.24 | 397.3 | -568.8 | -433 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 871.62 | 448.9 | -532.8 | -405.5 | ||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-equity | 692.24 | 397.3 | -568.8 | -433 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 871.62 | - | - | - | ||||||||||||||||
Total Investments | 1724.16 | 386.8 | 386.2 | 427.3 | ||||||||||||||||
balance-sheet.row.total-debt | 64.64 | 17.2 | 14 | 6.9 | ||||||||||||||||
balance-sheet.row.net-debt | -92.05 | -20.1 | -37.8 | -83.8 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -168.09 | -152.6 | -135.8 | -130.5 | ||||||||||||||||
cash-flows.row.depreciation-and-amortization | -2.39 | 0.8 | 0.8 | 0.6 | ||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -19.5 | 0 | 4.6 | ||||||||||||||||
cash-flows.row.stock-based-compensation | 21.24 | 28.1 | 26.3 | 23.6 | ||||||||||||||||
cash-flows.row.change-in-working-capital | 15.09 | 7.8 | -3 | -3.2 | ||||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.account-payables | 12.56 | 10.3 | -0.8 | -2.5 | ||||||||||||||||
cash-flows.row.other-working-capital | -0.6 | -2.5 | -2.2 | -0.7 | ||||||||||||||||
cash-flows.row.other-non-cash-items | -7.37 | 10.5 | 1.7 | 0.4 | ||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -137.8 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.22 | -0.2 | -0.6 | -1.1 | ||||||||||||||||
cash-flows.row.acquisitions-net | 0.01 | -15.6 | 0 | 0.1 | ||||||||||||||||
cash-flows.row.purchases-of-investments | -531.05 | -409.8 | -270.7 | -445.7 | ||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 440.36 | 425.5 | 303.9 | 320 | ||||||||||||||||
cash-flows.row.other-investing-activites | -0.01 | 15.6 | 0 | -0.1 | ||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -90.91 | 15.6 | 32.6 | -126.8 | ||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -9.4 | -7.3 | ||||||||||||||||
cash-flows.row.common-stock-issued | 240.6 | 94.8 | 24.7 | 4.4 | ||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.other-financing-activites | 97.43 | 94.8 | 23.3 | -0.6 | ||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 243.15 | 94.8 | 38.6 | -3.4 | ||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.net-change-in-cash | 14.24 | -14.5 | -38.9 | -234.8 | ||||||||||||||||
cash-flows.row.cash-at-end-of-period | 156.9 | 37.3 | 52 | 90.9 | ||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 142.66 | 51.8 | 90.9 | 325.7 | ||||||||||||||||
cash-flows.row.operating-cash-flow | -137.8 | -124.8 | -110.1 | -104.6 | ||||||||||||||||
cash-flows.row.capital-expenditure | -0.22 | -0.2 | -0.6 | -1.1 | ||||||||||||||||
cash-flows.row.free-cash-flow | -138.01 | -125 | -110.7 | -105.7 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 1.27 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.cost-of-revenue | 0.64 | 0.8 | 0.8 | 0.6 | ||||||||||||||||
income-statement-row.row.gross-profit | 0.63 | -0.8 | -0.8 | -0.6 | ||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.research-development | 126.31 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-general-administrative | 57.38 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.21 | - | - | - | ||||||||||||||||
income-statement-row.row.other-expenses | -2.5 | 0 | 4 | 0.8 | ||||||||||||||||
income-statement-row.row.operating-expenses | 183.48 | 165 | 139.9 | 131.3 | ||||||||||||||||
income-statement-row.row.cost-and-expenses | 183.69 | 165.8 | 139.9 | 131.3 | ||||||||||||||||
income-statement-row.row.interest-income | 11.86 | 14.7 | 4.3 | 1.2 | ||||||||||||||||
income-statement-row.row.interest-expense | 0.01 | 1.5 | 0.2 | 0.4 | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.21 | - | - | - | ||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 10.68 | 13.2 | 4.8 | 1.4 | ||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-operating-expenses | -2.5 | 0 | 4 | 0.8 | ||||||||||||||||
income-statement-row.row.total-operating-expenses | 10.68 | 13.2 | 4.8 | 1.4 | ||||||||||||||||
income-statement-row.row.interest-expense | 0.01 | 1.5 | 0.2 | 0.4 | ||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0.64 | 0.8 | 0.8 | 0.6 | ||||||||||||||||
income-statement-row.row.ebitda-caps | -174.06 | - | - | - | ||||||||||||||||
income-statement-row.row.operating-income | -174.89 | -165.8 | -140.6 | -131.8 | ||||||||||||||||
income-statement-row.row.income-before-tax | -168.09 | -152.6 | -135.8 | -130.5 | ||||||||||||||||
income-statement-row.row.income-tax-expense | 3.07 | 0 | 0.2 | -0.6 | ||||||||||||||||
income-statement-row.row.net-income | -168.09 | -152.6 | -136.1 | -129.9 |
Vaak gestelde vragen
Wat is Kura Oncology, Inc. (KURA) totale activa?
Kura Oncology, Inc. (KURA) totale activa is 448935000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is 1270000.000.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.331.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -117.767.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -127.669.
Wat is Kura Oncology, Inc. (KURA) nettowinst (netto-inkomen)?
De nettowinst is -152631000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 17200000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 164955000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 41506000.000.